PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

PepGen, Inc. (NASDAQ:PEPG) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $12.00.

Several research firms have recently weighed in on PEPG. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright increased their price objective on shares of PepGen from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Finally, Guggenheim upped their price target on PepGen from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday.

PepGen Stock Performance

NASDAQ PEPG opened at $6.22 on Friday. The business has a fifty day moving average price of $5.76 and a 200 day moving average price of $4.40. The company has a market cap of $427.63 million, a P/E ratio of -2.21 and a beta of 1.91. PepGen has a one year low of $0.88 and a one year high of $7.80.

Institutional Trading of PepGen

A number of hedge funds and other institutional investors have recently modified their holdings of PEPG. Rangeley Capital LLC boosted its position in shares of PepGen by 133.3% during the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after acquiring an additional 20,000 shares during the last quarter. Marshall Wace LLP purchased a new position in PepGen during the second quarter worth about $44,000. Heights Capital Management Inc. acquired a new position in PepGen in the 3rd quarter valued at about $46,000. Burkehill Global Management LP acquired a new position in PepGen in the 3rd quarter valued at about $46,000. Finally, Militia Capital Partners LP purchased a new stake in shares of PepGen in the 3rd quarter valued at approximately $72,000. 58.01% of the stock is owned by institutional investors and hedge funds.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).